AtriCure saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 82.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
AtriCure is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could spark a new run.
The company posted 0% EPS growth last quarter. Revenue rose 18%.
AtriCure earns the No. 19 rank among its peers in the Medical-Systems/Equipment industry group. Electromed, Intuitive Surgical and iRadimed are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
